NCT05118516View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions
Healthy Volunteer
Interventions
DRUG

ASC43F

One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.

Trial Locations (1)

78209

8307 Gault Lane, San Antonio

Sponsors
All Listed Sponsors
lead

Gannex Pharma Co., Ltd.

INDUSTRY

NCT05118516 - Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects | Biotech Hunter | Biotech Hunter